Global /China /Healthcare /Drug Manufacturers - General /688513

Chengdu Easton Biopharmaceuticals Co., Ltd.

688513

• SSE: 688513 • Delayed

64.38CNY 1%

9.51 USD

As of 16 June 2026, Chengdu Easton Biopharmaceuticals Co., Ltd. has a market cap of $1.64B USD, ranking #8000 globally and #2037 in China. It ranks #670 in the Healthcare sector, and #258 in the Drug Manufacturers - General industry.

Global Rank

8000

Country Rank

2037

Sector Rank

670

Industry Rank

258

Key Stats

Market Cap

$1.64BUSD

11.12B CNY

Enterprise Value

$1.43BUSD

9.68B CNY

Revenue (TTM)

$199.67MUSD

1.35B CNY

EBITDA (TTM)

$49.0MUSD

331.57M CNY

Net Income (TTM)

$40.51MUSD

274.3M CNY

EBITDA Margin

25%

Profit Margin

20%

PE Ratio

40.3

Forward PE

36.6

PS Ratio

8.2

PB Ratio

3.6

EV/EBITDA

29.2

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mingxu Yuan open_in_new

Employees

1,522

Founded

2009

Website

eastonpharma.cn open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1%	-1.5%	-4.3%	7.7%	18%	3.2%	91%	64%	116%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688513 成都苑东生物制药股份有限公司 Class A ISIN: CNE100004397 Shares Out.: Shares Outstanding: 174.353M¹ Shares Float: 80.644M² TV: TradingView: SSE: 688513 SA: Stock Analysis: SHA: 688513 YF: Yahoo Finance: 688513.SS GF: Google Finance: SHA: 688513 BA: Barron's: 688513 MS: Morningstar: XSHG: 688513	64.38 CNY	TV: TradingView: SSE: 688513 SA: Stock Analysis: SHA: 688513 YF: Yahoo Finance: 688513.SS GF: Google Finance: SHA: 688513 BA: Barron's: 688513 MS: Morningstar: XSHG: 688513

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Chengdu Easton Biopharmaceuticals Co., Ltd.

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricaracetam and Lacosamide for neurological and psychiatric applications; and Empagliflozin for anti-diabetic applications. The company was founded in 2009 and is based in Chengdu, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.89B 364.89B CNY 3K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.67B 336.36B CNY 3K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 2K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 1K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.52B 111.89B CNY 906%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 875%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 46K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 33K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 22K%	97.4	United States
Roche Holding AG SIX: RO	$320.51B 256.25B CHF 19K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.14B 215.59B GBP 17K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 17K%	15.1	United States

chevron_leftBack